Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Invitrogen™ Cathepsin K Polyclonal Antibody

Rabbit Polyclonal Antibody
Supplier: Invitrogen™ PA5109606
Description
Immunogen sequence: APDSVDYRKK GYVTPVKNQG QCGSCWAFSS VGALEGQLKK KTGKLLNLSP QNLVDCVSEN DGCGGGYMTN AFQYVQKNRG IDSEDAYPYV GQEESCMYNP TGKAAKCRGY REIPEGNEKA LKRAVARVGP VSVAIDASLT SFQFYSKGVY YDESCNSDNL NHAVLAVGYG IQKGNKHWII KNSWGENWGN KGYILMARNK NNACGIANLA SFPKM.
The protein encoded by this gene is a lysosomal cysteine proteinase involved in bone remodeling and resorption. This protein, which is a member of the peptidase C1 protein family, is predominantly expressed in osteoclasts. However, the encoded protein is also expressed in a significant fraction of human breast cancers, where it could contribute to tumor invasiveness. Mutations in this gene are the cause of pycnodysostosis, an autosomal recessive disease characterized by osteosclerosis and short stature. This gene may be subject to RNA editing.
Specifications
| Cathepsin K | |
| Polyclonal | |
| Unconjugated | |
| CTSK | |
| AI323530; Cat K; cathepsin K; Cathepsin O; cathepsin O1; cathepsin O2; Cathepsin X; catK; CTS02; CTSK; CTSO; CTSO1; CTSO2; MGC23107; minisatellite 10q detected by probe MMS10; MMS10-Q; Ms10q; PKND; PYCD | |
| Rabbit | |
| Affinity Chromatography | |
| RUO | |
| 13038, 1513, 29175 | |
| -20°C, Avoid Freeze/Thaw Cycles | |
| Liquid |
| ELISA, Western Blot | |
| 0.15 mg/mL | |
| PBS with 50% glycerol and 0.05% ProClin 300; pH 7.3 | |
| O35186, P43235, P55097 | |
| CTSK | |
| Recombinant fusion protein containing a sequence corresponding to amino acids 115-329 of human CTSK (NP_000387.1). | |
| 100 μL | |
| Primary | |
| Human, Mouse, Rat | |
| Antibody | |
| IgG |
Safety and Handling
WARNING: Cancer - www.P65Warnings.ca.gov
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction